SCIENTIFIC PROGRAM

SUBSTRATES ANALYSIS AND RISK ASSESSMENT IN ARRHYTHMOGENIC CARDIOMYOPATHIES: THE ROLE OF CMR

Session 1 – Monday, December 14, 2020

Arrhythmic Mitral Valve Prolapse

INTRODUCTION: Focus on Mitral Valve Prolapse
S. Iliceto (Padua, Italy)
Morphological substrates of arrhythmias
M. Perazzolo Marra (Padua, Italy)
Role of cardiac imaging in the diagnosis
K. Haugaa (Oslo, Norway)
Arrhythmic risk stratification
F.N. Delling (San Francisco, USA)
State-of-the-art: Mitral Annular Disjunction
A.P.W. Lee (Hong Kong, China)
DISCUSSION
S. Iliceto (Padua, Italy) – Panelists

Session 2 – Tuesday, December 15, 2020

Focus on ACM

INTRODUCTION: Focus on ACM
B. Bauce (Padua, Italy)
Pathological hallmarks

G. Thiene (Padua, Italy)
CMR: When and Why?
V. Ferrari (Philadelphia, USA)
CMR and SCD Risk Assessment in ACM
A. Te Riele (Utrecht, The Netherlands)
State-of-the-art: Updated Diagnostic Criteria
D. Corrado (Padua, Italy)
DISCUSSION
B. Bauce (Padua, Italy) – Panelists

Session 3 – Monday, December 21, 2020

Dilated and Inflammatory Cardiac Disease

INTRODUCTION: Focus on Inflammatory Cardiac Disease
C. Bucciarelli Ducci (Bristol, United Kingdom)
Diagnosis? Endomyocardial Biopsy
A.L.P. Caforio (Padova, Italy)
Diagnosis? CMR is enough
V. Ferreira (Oxford, United Kingdom)
Prognostic value of tissue characterization
B. Halliday (London, United Kingdom)
State-of-the-art: Map to the future
M. Friedrich (Calgary, Canada)
DISCUSSION
C. Bucciarelli Ducci (Bristol, United Kingdom) – Panelists

Session 4 – Tuesday, December 22, 2020

Hypertrophic Cardiomyopathy

INTRODUCTION: Focus on Hypertrophic Cardiomyopathy
P. Elliott (London, United Kingdom)
CMR diagnostic features
M. Maron (Boston, USA)
Prognostic value of tissue characterization
S. Neubauer (Oxford, United Kingdom)
New techniques in CMR
D. Pennell (London, United Kingdom)
State-of-the-art: Arrhythmic risk stratification
W. McKenna (Doha, Qatar/London, United Kingdom)
DISCUSSION
P. Elliott (London, United Kingdom) – Panelists

Session 5 – Monday January 11, 2021

Rare Cardiomyopathies

INTRODUCTION: Focus on CMR in Rare Cardiomyopathies
J. Moon (London, United Kingdom)
CMR in muscular dystrophies
S. Mavrogeni (Athens, Greece)
CMR in Chagas cardiomyopathy
C.E. Rochitte (Sao Paulo, Brazil)
CMR in cardiac sarcoidosis
C. Shenoy (Minneapolis, USA)
State-of-the-art: CMR in cardiac amyloidosis
M. Fontana (London, United Kingdom)
DISCUSSION
J. Moon (London, United Kingdom) –Panelists

Session 6 – Tuesday January 12, 2021

Coronary Artery Disease

INTRODUCTION: Focus on CMR in coronary artery disease
S. Plein (Leeds, United Kingdom)
CMR in stress perfusion
R. Kwong (Boston, USA)
CMR in microvascular injury
C. Berry (Glasgow, United Kingdom)
CMR in MINOCA
C. Bucciarelli Ducci (Bristol, United Kingdom)
State-of-the-art: CMR and myocardial viability
P.G. Masci (London UK)
DISCUSSION
S. Plein (Leeds, United Kingdom) – Panelists

Session 7 – Monday January 18, 2021

Sport Activity and Arrhythmias

INTRODUCTION: Focus on CMR in SCD prevention in athletes
F. Migliore (Padua, Italy)
ECG and arrhythmic red flags
A. Zorzi (Padua, Italy)
The role of cardiac imaging in sport cardiology
M. Papadakis (London, UK)
The role of CMR in the risk assessment
A. La Gerche (Melbourne, Australia)
State-of-the-art: Risk stratification for sport activity in cardiomyopathies
A. Pelliccia (Rome, Italy)
DISCUSSION      
F. Migliore (Padua, Italy) – Panelists

Session 8 – Tuesday January 19, 2021

Therapeutic Strategies

INTRODUCTION: primary prevention of sudden cardiac death in arrhythmogenic cardiomyopathies
G. Boriani (Modena, Italy)
Primary prevention of sudden cardiac death in non ischemic dilated cardiomyopathies
E. Bertaglia (Padua, Italy)
The right device in the right patient
Federico Migliore (Padua, Italy)
Long-term outcomes of ablation for ventricular arrhythmias in mitral valve prolapse
F.N. Delling (San Francisco, USA)
State-of-the-art: Electroanatomic mapping: from arrhytmogenic substrate to therapeutic ablation
P. Della Bella (Milan, Italy)
DISCUSSION      
G. Boriani (Modena, Italy) – Panelists

Session 9 – Monday January 25, 2021

When and for Whom to Request CMR?

INTRODUCTION: the role of CMR in clinical practice
Z. Jing (Beijing, China) – S. Iliceto (Padua, Italy)
When in mitral valve prolapse? 
R. Bonow (Chicago, USA)
When in ARVC?
D. Corrado (Padua, Italy)
When in cardiomyopathies?       
R. Sukmawan (Jakarta, Indonesia)
When in coronary artery disease?
W. El Tahlawy (Abu Dhabi, United Arab Emirates)
When pathology is still essential?
C. Basso (Padua, Italy)
State-of-the-art: When echocardiography can avoid CMR?
L.P. Badano (Milan, Italy)
DISCUSSION      
Z. Jing (Beijing, China)- S. Iliceto (Padua, Italy) – Panelists